Core Viewpoint - The company has reported a total accounts receivable of RMB 128 million as of December 31, 2024, with adequate impairment provisions made according to accounting standards, primarily arising from routine business operations [1] Group 1: Collection Efforts - For related party receivables, the company has established a special working mechanism and has successfully recovered RMB 11.0869 million by November 30, 2025, with ongoing legal proceedings for unrecovered amounts [1] - For non-related party receivables, the company has reached agreements with cooperative clients, resulting in additional recoveries of RMB 4.4514 million, with repayment plans being executed steadily [2] - For clients with long overdue accounts or operational difficulties, the company has engaged third-party professionals for assessment and initiated legal procedures to protect its rights [2] Group 2: Internal Management Optimization - The company has established an "Accounts Receivable Management Committee" led by the finance department to enhance collection efforts and has strengthened internal controls from customer credit assessment to payment term management to prevent new risks [3] Group 3: Future Plans - The company will continue to take all necessary legal and compliant measures to maximize the recovery of receivables, including ongoing negotiations, arbitration execution, and civil litigation preparations, with regular progress reports to the board [4]
中国医疗集团：截至11月末已成功收回关联方款项合计1108.69万元